CEO Interview: Jeff Stein, Trius Therapeutics (TSRX)
Trius Therapeutics (TSRX) is a speculative biotech company focusing on treating drug resistant bacteria. Its lead product to treat skin infections could get approval by 2014, and may potentially be a billion dollar drug. The stocks has doubled since the beginning of the year. Cramer recommended buying it then selling it because it had gotten "too hot," but it has rallied over a dollar since. For those who want to buy TSRX, Cramer recommended using limit orders. CEO Jeff Stein is optimistic the FDA will approve its drugs because of the growing problem of "superbugs" that are resistant to other forms of antibiotics. "This is a hot stock," Cramer said, "but they are doing what the FDA wants them to do."